Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S.

August 21st, 2014 ITI moves one step closer to a solution for the worldwide allergy crisis DNA vaccine pioneer Immunomic Therapeutics, Inc.(ITI) is making progress in its development of JRC-LAMP-vax, an innovative and safe potential treatment for allergy to Japanese red cedar pollen. Phase IC studies began this month in Hawaii, moving the world closer to a real solution to hay …

Researchers to examine whether BCG vaccine combats allergies

Researchers in Australia are about to embark on a trial examining whether the BCG vaccine against TB could also protect against allergic sensitization. The BCG vaccine was phased out of the the Australian immunization schedule three decade ago, and in recent years the country has experienced skyrocketing allergy rates. Melbourne researchers hypothesize that the two could be linked, and will …

Download: Allergy Vaccine eBook

In the United States, 65 million people have some type of allergy. In Europe, that number goes up to 87 million. Fifty six percent are allergic to grasses in the US versus 52% in Europe. Cat allergies are 39% in the US and 30% in Europe and food allergies are 10% in the US and 11 % in Europe. The …

Climate change in vaccine trials: Moving from a one-size-fits-all to a custom fit in operational delivery

Dr Vigdorth has 30 years of drug development research experience in the clinical setting and pharmaceutical and CRO industries. She has led clinical development programs across a range of therapeutic indications with extensive experience in antibiotic, antiviral, vaccine, and antifungal agents.   Dr Vigdorth's experience has developed from multiple perspectives including working in the clinical investigative site setting, multi- national …